Uke Perpetual, Maharaj Ajesh, Adebajo Adewale
Department of Rheumatology, Birmingham City Hospital, United Kingdom; Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, United Kingdom.
Department of Internal Medicine and Pharmacology, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South Africa.
Best Pract Res Clin Rheumatol. 2025 Mar;39(1):102036. doi: 10.1016/j.berh.2025.102036. Epub 2025 Feb 11.
Rheumatoid arthritis (RA) is a systemic, chronic autoimmune disease affecting mainly the joints, often with extra articular manifestations. This review provides an update on RA epidemiological trends and management. PubMed and EMBASE were searched from 2014 to 2024 using rheumatoid arthritis as keyword, combined with incidence, prevalence, diagnosis, classification, and management. Emphasis was on papers published in the past 5 years. Globally, the age-standardised prevalence and incidence rate (ASPR and ASIR) of RA increased with varying figures. The ASPR increased by 0.37%, 14.1%, and 6.4% from 1990 to 2019, 2020 and 2017 respectively; and 9% from 1980 to 2019. The ASIR increased by 0.3% and 8.2% from 1990 to 2019 and 2017 respectively; the disability-adjusted life years (DALY) figures increased 0.12% and decreased 0.36% in the same period from different authors. Reduction in ASIR were reported while ASPR varies. Disease modifying anti-rheumatic drugs (DMARDs) remain the cornerstone of treatment.
类风湿关节炎（RA）是一种全身性慢性自身免疫性疾病，主要影响关节，常伴有关节外表现。本综述提供了类风湿关节炎流行病学趋势和管理方面的最新信息。使用类风湿关节炎作为关键词，结合发病率、患病率、诊断、分类和管理，检索了2014年至2024年的PubMed和EMBASE数据库。重点关注过去5年发表的论文。在全球范围内，类风湿关节炎的年龄标准化患病率和发病率（ASPR和ASIR）呈现出不同程度的上升。从1990年到2019年、2020年和2017年，ASPR分别上升了0.37%、14.1%和6.4%；从1980年到2019年上升了9%。从1990年到2019年和2017年，ASIR分别上升了0.3%和8.2%；不同作者报告的残疾调整生命年（DALY）数据在同一时期分别上升了0.12%和下降了0.36%。有报告称ASIR有所下降，而ASPR则有所不同。改善病情抗风湿药物（DMARDs）仍然是治疗的基石。
